(S,E)-N-(2-(Diethylamino)ethyl)-2-(3-oxotetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-1-ylidene)-N-((2'-(2,2,2-trifluoroethoxy)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)acetamide

ID: ALA4638207

Chembl Id: CHEMBL4638207

PubChem CID: 156012800

Max Phase: Preclinical

Molecular Formula: C30H33F6N3O4

Molecular Weight: 613.60

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2OCC(F)(F)F)cc1)C(=O)/C=C1/OC(=O)N2CCC[C@@H]12

Standard InChI:  InChI=1S/C30H33F6N3O4/c1-3-37(4-2)14-15-38(27(40)17-26-24-6-5-13-39(24)28(41)43-26)18-20-7-9-21(10-8-20)23-12-11-22(30(34,35)36)16-25(23)42-19-29(31,32)33/h7-12,16-17,24H,3-6,13-15,18-19H2,1-2H3/b26-17+/t24-/m0/s1

Standard InChI Key:  DYOHDHMNXATIDC-MSIOFZDNSA-N

Alternative Forms

  1. Parent:

    ALA4638207

    ---

Associated Targets(Human)

PLA2G7 Tchem LDL-associated phospholipase A2 (1338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 613.60Molecular Weight (Monoisotopic): 613.2375AlogP: 6.48#Rotatable Bonds: 11
Polar Surface Area: 62.32Molecular Species: BASEHBA: 5HBD:
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): #RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 9.01CX LogP: 5.40CX LogD: 3.78
Aromatic Rings: 2Heavy Atoms: 43QED Weighted: 0.21Np Likeness Score: -1.01

References

1. Huang F, Hu H, Wang K, Peng C, Xu W, Zhang Y, Gao J, Liu Y, Zhou H, Huang R, Li M, Shen J, Xu Y..  (2020)  Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.,  63  (13): [PMID:32459096] [10.1021/acs.jmedchem.0c00372]
2. de Esch IJP, Erlanson DA, Jahnke W, Johnson CN, Walsh L..  (2022)  Fragment-to-Lead Medicinal Chemistry Publications in 2020.,  65  (1.0): [PMID:34928151] [10.1021/acs.jmedchem.1c01803]

Source